View in EDS

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.

Saved in:
Bibliographic Details
Title: Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
Authors: Schöffski P; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium., Tan DSW; National Cancer Centre Singapore, Singapore.; Duke-NUS Medical School, Singapore., Martín M; Hospital General Universitario Gregorio Maranon, Madrid, Spain., Ochoa-de-Olza M; Vall d'Hebron University Hospital, Barcelona, Spain., Sarantopoulos J; Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, Texas, USA., Carvajal RD; Columbia University Irving Medical Center, New York, New York, USA., Kyi C; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Esaki T; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Prawira A; Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., Akerley W; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., De Braud F; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy., Hui R; Westmead Hospital and The University of Sydney, Sydney, New South Wales, Australia., Zhang T; University of Texas Southwestern Medical Center, Dallas, Texas, USA., Soo RA; National University Cancer Institute, Singapore., Maur M; Oncologia Medica, AOU Policlinico di Modena, Modena, Emilia-Romagna, Italy., Weickhardt A; Austin Health, Heidelberg, Victoria, Australia., Krauss J; National Center for Tumor Diseases, Heidelberg, Germany., Deschler-Baier B; Universitätsklinikum Würzburg, Wurzburg, Germany., Lau A; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Samant TS; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Longmire T; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Chowdhury NR; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Sabatos-Peyton CA; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Patel N; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Ramesh R; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Hu T; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Carion A; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Gusenleitner D; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Yerramilli-Rao P; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Askoxylakis V; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Kwak EL; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA., Hong DS; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA dshong@mdanderson.org.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Feb; Vol. 10 (2).
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35217575
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Schöffski+P%22">Schöffski P</searchLink>; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Tan+DSW%22">Tan DSW</searchLink>; National Cancer Centre Singapore, Singapore.; Duke-NUS Medical School, Singapore.<br /><searchLink fieldCode="AU" term="%22Martín+M%22">Martín M</searchLink>; Hospital General Universitario Gregorio Maranon, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Ochoa-de-Olza+M%22">Ochoa-de-Olza M</searchLink>; Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Sarantopoulos+J%22">Sarantopoulos J</searchLink>; Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Carvajal+RD%22">Carvajal RD</searchLink>; Columbia University Irving Medical Center, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Kyi+C%22">Kyi C</searchLink>; Memorial Sloan Kettering Cancer Center, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Esaki+T%22">Esaki T</searchLink>; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Prawira+A%22">Prawira A</searchLink>; Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Akerley+W%22">Akerley W</searchLink>; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.<br /><searchLink fieldCode="AU" term="%22De+Braud+F%22">De Braud F</searchLink>; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Hui+R%22">Hui R</searchLink>; Westmead Hospital and The University of Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Zhang+T%22">Zhang T</searchLink>; University of Texas Southwestern Medical Center, Dallas, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Soo+RA%22">Soo RA</searchLink>; National University Cancer Institute, Singapore.<br /><searchLink fieldCode="AU" term="%22Maur+M%22">Maur M</searchLink>; Oncologia Medica, AOU Policlinico di Modena, Modena, Emilia-Romagna, Italy.<br /><searchLink fieldCode="AU" term="%22Weickhardt+A%22">Weickhardt A</searchLink>; Austin Health, Heidelberg, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Krauss+J%22">Krauss J</searchLink>; National Center for Tumor Diseases, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Deschler-Baier+B%22">Deschler-Baier B</searchLink>; Universitätsklinikum Würzburg, Wurzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Lau+A%22">Lau A</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Samant+TS%22">Samant TS</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Longmire+T%22">Longmire T</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Chowdhury+NR%22">Chowdhury NR</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Sabatos-Peyton+CA%22">Sabatos-Peyton CA</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Patel+N%22">Patel N</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Ramesh+R%22">Ramesh R</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hu+T%22">Hu T</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Carion+A%22">Carion A</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Gusenleitner+D%22">Gusenleitner D</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Yerramilli-Rao+P%22">Yerramilli-Rao P</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Askoxylakis+V%22">Askoxylakis V</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Kwak+EL%22">Kwak EL</searchLink>; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA dshong@mdanderson.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2022 Feb; Vol. 10 (2).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35217575
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1136/jitc-2021-003776
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Schöffski P
      – PersonEntity:
          Name:
            NameFull: Tan DSW
      – PersonEntity:
          Name:
            NameFull: Martín M
      – PersonEntity:
          Name:
            NameFull: Ochoa-de-Olza M
      – PersonEntity:
          Name:
            NameFull: Sarantopoulos J
      – PersonEntity:
          Name:
            NameFull: Carvajal RD
      – PersonEntity:
          Name:
            NameFull: Kyi C
      – PersonEntity:
          Name:
            NameFull: Esaki T
      – PersonEntity:
          Name:
            NameFull: Prawira A
      – PersonEntity:
          Name:
            NameFull: Akerley W
      – PersonEntity:
          Name:
            NameFull: De Braud F
      – PersonEntity:
          Name:
            NameFull: Hui R
      – PersonEntity:
          Name:
            NameFull: Zhang T
      – PersonEntity:
          Name:
            NameFull: Soo RA
      – PersonEntity:
          Name:
            NameFull: Maur M
      – PersonEntity:
          Name:
            NameFull: Weickhardt A
      – PersonEntity:
          Name:
            NameFull: Krauss J
      – PersonEntity:
          Name:
            NameFull: Deschler-Baier B
      – PersonEntity:
          Name:
            NameFull: Lau A
      – PersonEntity:
          Name:
            NameFull: Samant TS
      – PersonEntity:
          Name:
            NameFull: Longmire T
      – PersonEntity:
          Name:
            NameFull: Chowdhury NR
      – PersonEntity:
          Name:
            NameFull: Sabatos-Peyton CA
      – PersonEntity:
          Name:
            NameFull: Patel N
      – PersonEntity:
          Name:
            NameFull: Ramesh R
      – PersonEntity:
          Name:
            NameFull: Hu T
      – PersonEntity:
          Name:
            NameFull: Carion A
      – PersonEntity:
          Name:
            NameFull: Gusenleitner D
      – PersonEntity:
          Name:
            NameFull: Yerramilli-Rao P
      – PersonEntity:
          Name:
            NameFull: Askoxylakis V
      – PersonEntity:
          Name:
            NameFull: Kwak EL
      – PersonEntity:
          Name:
            NameFull: Hong DS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2022 Feb
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2051-1426
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Journal for immunotherapy of cancer
              Type: main
ResultId 1